黄豆黄素和黄豆黄苷抗癌作用机制差异分析

Analysis of the Different Anti-Cancer Mechanisms between Glycitein and Glycitin

近年来,乳腺癌已超过肺癌成为最常见的癌症。此外,宫颈癌也对妇女的生活造成重大负担。细胞色素酶CYP1B1在肝外组织中的表达是这些癌症发病的关键因素,因此通过破坏CYP1B1酶与底物的结合,或消除其反应产物,是实现保护人类健康的方法。黄豆黄素和黄豆黄苷是从大豆中提取的两种异黄酮类化合物,具有抗癌的潜力,然而它们的作用机制尚不清楚。通过体外实验证明二者的抗癌作用存在差异,并通过结构和量子化学计算等研究辅助分析构效差异,分析了他们在抗癌作用中的作用机制,并发现他们的结构差异可能是作用机制差异的原因,为未来更多抗癌药物的开发提供了理论基础。

Breast cancer has become the most common cancer in recent years,surpassing lung cancer.Cervical cancer also poses a significant burden on women′s lives.The pathogenesis of these cancers is closely related to the expression of the cytochrome enzyme CYP1B1 in extrahepatic tissues.Therefore,protecting human health could be achieved by disrupting the binding of the CYP1B1 enzyme to its substrates or by eliminating its reaction products.Glycitein and glycitin are two isoflavones extracted from soybeans that have potential anti-cancer properties.However,their mechanism of action is still unclear.In vitro experiments showed differences in their anticancer effects.Structural and quantum chemical calculations were used to analyze the differences in structure-activity relationship and mechanism of anticancer effects,which may be the mechanism of action.These findings provide a theoretical basis for designing anti-cancer drugs in the future.